Printer Friendly

Enzymatic assay of calcium in serum with phospholipase D.

Various methods for determining calcium in body fluids have been reported. Atomic absorption spectrophotometry (AAS) (1) is a most reliable method; however, because the AAS instrument is expensive and maintenance is difficult, it is unsuitable for routine assay. Spectrophotometric methods by use of o-cresolphthalein complexone (CPC) (2-6), which is based on chelation, is now widely available to assay calcium in clinical laboratories. Several enzymatic methods that use porcine pancreatic [alpha]-amylase (EC (7) or phospholipase D (PLD; EC (8) to measure calcium have also been developed. These methods are based on the activation of the enzymes by calcium. On the other hand, Kimura et al. (9) reported a kinetic assay for calcium in serum that uses urea amidolyase (EC based on the inhibition of the enzyme by calcium. Previously reported method for determining free calcium ions in serum using PLD required appropriate ionic strength for its reaction (8). We have established a new and stable enzymatic method for determining calcium in serum that uses PLD, stabilizing calcium status by adding a large excess of bovine albumin to the reaction system.

The proposed enzymatic method for determining calcium in serum is based on the following sequence of reactions:


Diacetylphosphatidylcholine (DAPC) is used for the PLD reaction substrate. The reaction rate at which PLD hydrolyzes DAPC into choline and diacetylphosphatidic acid depends on the amount of calcium in serum. Choline oxidase (COD) produces Betaine and [H.sub.2][O.sub.2] from choline and [O.sub.2.] Peroxidase (POD) produces quinone from HZOZ with 4-aminoantipyrine (4-AA) and N-ethyl-N-(3-methylphenyl)-N'-succinyl-ethylenediamine (EMSE). The absorbance at 546 nm for the quinone dye is measured.

This proposed method and the conventional methods were performed with the Hitachi Model 7170 automated analyzer.

PLD (10.7 kU/g, from Streptomyces scabies) was purchased from Kyowa Hakko Kogyo; the Determiner PL kit was from Kyowa Medex; EMSE was from Daito Chemix; acetonitrile and silica gel 60-F254 thin-layer chromatography plates were from Kanto Chemical; and glycerophosphatidylcholine was from Nippon Oil Fats. COD (18.1 kU/g, from Alcaligenes sp.) and POD (110 kU/g, from horseradish) were purchased from Toyobo. HEPES was purchased from Dojindo Laboratories; 4-AA, ascorbic acid, acetic anhydride, Mg[Cl.sub.2], Ca[Cl.sub.2], [KH.sub.2][PO.sub.4], Zn[Cl.sub.2], Fe[Cl.sub.3], Cu[SO.sub.4] x 5 [H.sub.2]O, sodium citrate, dipotassium EDTA, and silica gel 60-80 were from Wako Pure Chemical Industries; bilirubin and bovine albumin were from Sigma; and Intralipid 10% was from Kabi Vitrum AB. Chelex 100 resin was purchased from Bio-Rad Laboratories.

Serum specimens were collected from patients in Nagoya University Hospital. We obtained informed consent from patients to measure their serum calcium for this study.

The synthesis and purification of DAPC was as follows: Glycerophosphatidylcholine (12 g) was dissolved with 120 mL of acetic anhydride and allowed to stand at 80[degrees]C for 4 h. The 120-mL reaction mixture was applied to a silica gel column (80 x 800 mm; gel volume, 4 L), and eluted with 600 mL/L acetonitrile at 20 mL/min as 100-mL fractions. The DAPC-rich fraction was collected and concentrated by evaporator to yield 11.8 g of DAPC. The detection of DAPC was as followed: 20 [micro]L of every fraction was applied to silica gel thin-layer chromatography plates, and the chromatogram was developed with 600 mL/L acetonitrile. Determiner PL kit was added to the silica gel thin-layer chromatography plates for the detection of DAPC, with reaction at 37[degrees]C for 10 min.

PLD solution, bovine albumin solution, and pooled human serum without calcium were prepared as follows: calcium and other metals were removed from the 30 kU/L PLD solution, 20 g/L bovine albumin solution, and pooled human serum by Chelex 100 resin batch method, with ~1 g of resin added to ~10 mL of the PLD, the bovine albumin solution, and the pooled human serum. The solution was stirred gently for ~30 min and decanted from the resin. Each supernatant was repeatedly treated with Chelex 100 resin in the same way. We confirmed the removal of the calcium in this treated solution by AAS, the CPC method, and another enzymatic method.

Reagent 1 contained 3.0 kU/L PLD (calcium free), 3.0 kU/L COD, 40 kU/L POD, 2.5 mmol/L EMSE, and 2.0 g/L bovine albumin (calcium free) in 100 mmol/L HEPES buffer (pH 7.5). Reagent 2 contained 3.0 mmol/L DAPC and 6.4 mmol/L 4-AA in 100 mmol/L HEPES buffer (pH 7.5).

Calibrators were sera containing 1.5, 2.0, 2.5, 3.0, and 4.0 mmol/L calcium, which were prepared by dissolving Ca[Cl.sub.2] in the calcium-free pooled human serum. We confirmed that the calcium values of calibrators were exactly the same as those examined by AAS, the CPC method, and another enzymatic method.

The assay was performed with the Rate A mode of the Hitachi 7170 automated analyzer. Three microliters of calcium calibrators (0-4.0 mmol/L) or patient serum and 240 [micro]L of reagent 1 were poured into the reaction cuvettes; after the mixtures were incubated for 5 min at 37[degrees]C, 60 [micro]L of reagent 2 was added. The reaction rate was measured at 25-34 time points (7.35-10.0 min) at 546 nm. The calcium values of sera from patients were calculated from the calibration curve obtained with 0-4.0 mmol/L calcium calibrators. The six-point calibration curve was a sigmoid curve that corresponded to the calcium values (Fig. 1A). However, the color development of the calcium aqueous solution was impaired; therefore, calcium aqueous solution could not be used for the calibrators.


We also measured the concentrations of calcium in sera from patients by a CPC method (Calcium-HR II kit from Wako Pure Chemical Industries), and another enzymatic method (Diacolor Ca kit from Ono Pharmaceutical) based on the activities of porcine pancreatic a-amylase. The measurement of calcium by AAS (1) was carried out on the Hitachi Z-6100 Polarized Zeeman Atomic Absorption Spectrophotometer.

Optimization studies of this proposed method were carried out with the calibrator (2.50 mmol/L calcium), and two patient sera (1.50 and 2.10 mmol/L calcium). The effects of pH on the calcium determination were examined in 100 mmol/L HEPES buffer at various pH values (6.5, 7.0, 7.5, 8.0, and 8.5). The maximum reaction rate ([A.sub.10 min] - [A.sub.7.35 min] the calibrator was observed at pH 7.5, and the calcium values of the patients' sera were almost stable at various pHs; therefore, pH 7.5 HEPES buffer was used. The reaction rate of the calibrator increased with increasing PLD activity and DAPC concentration. We chose the lowest PLD activity and DAPC concentration, 2.4 kU/L and 0.6 mmol/L, respectively, in the range of minimum variations of calcium values of the patients' sera.

We next added a large excess of bovine albumin to the reaction system to avoid the effects of albumin contained in specimens. With increasing bovine albumin concentration, the reaction rate of the calibrator gradually decreased. Bovine albumin (1.6 g/L) was added to the reaction system because this concentration brought about minimum variation of the calcium values of the patients' sera. A decrease of calcium values caused by albumin (20-100 g/L) added to calcium aqueous solution was therefore prevented.

We also determined the optimal concentrations of COD, POD, 4-AA, and EMSE in the same way; the optimal concentrations were 2.4 kU/L for COD, 32 kU/L for POD, 1.28 mmol/L for 4-AA, and 2.0 mmol/L for EMSE.

Typical time courses of reactions were carried out for the calibrator (2.50 mmol/L calcium), a patient's serum (2.32 mmol/L calcium), and reagent blank by this proposed kinetic calcium assay. When reagent 2 was added to the mixtures of serum and reagent 1, the color for produced quinone dye was developed. A lag phase up to ~60 s was observed, but after that the absorbance of color development was linear. The slight increase of absorbance for the reagent blank was recognized. We chose to measure between 7.35 and 10.0 min.

The precision of our assay were determined by using of pooled serum L, pooled serum M, and pooled serum H, which contained 1.92, 2.25, and 2.65 mmol/L calcium, respectively. Within-assay CVs were determined with 20 replicates of each sample, and day-to-day CVs were determined from assays performed on 10 different days. As shown in Table 1, the within-assay CV was 0.450.55%, and the day-to-day CV was 1.2-1.8%.

The recoveries were determined using pooled human serum (2.27 mmol/L calcium) supplemented with calcium (0.25, 0.50, 0.75, 1.00, 1.25, and 1.50 mmol/L). Recoveries were 92.0-108.0% (mean, 102.6%).

The influences of various substances on this calcium determination method were examined with a pooled human serum (2.00 mmol/L calcium). The interference [interference (%) = (calcium value of test--calcium value of control)/calcium value of control x 100] was calculated. We found no interference with the calcium determination from ascorbic acid up to 1.14 mmol/L, bilirubin up to 0.342 mmol/L, Intralipid up to 100-fold diluted (0.10%), Mg[Cl.sub.2] up to 5.0 mmol/L, NaCl up to 200 mmol/L, KI up to 10.0 mmol/L, Fe[Cl.sub.3] up to 1.0 mmol/L, Cu[SO.sub.4] up to 1.0 mmol/L, and Zn[Cl.sub.2] up to 0.1 mmol/L, all in serum (less than [+ or -] 3%). On the other hand, the calcium value decreased with calcium-chelating agents such as 1.0 g/L sodium citrate (-8.7%) or 1.0 g/L EDTA (-92.3%) used for banked blood, and with 1.0 g/L hemoglobin (-7.0%); calcium values increased with 5.0 mmol/L KHZP04 (8.5%) in serum. However, plasma from 20 patients prepared with heparin showed no interference. We next measured the calcium values of sera from patients with multiple myeloma. Only 1 of the 11 sera showed a decreased value (-7.6%).

The color developments of calibrators and patient serum decreased ~20% by use of reagents 1 and 2 that were kept at 4[degrees]C for 10 days; however, the calcium values of sera from patients were not changed.

We examined the correlation between this proposed method and AAS for 42 patient serum samples (Fig. 1B). The correlation between calcium values obtained with this proposed method (y) and those obtained with AAS (x) was: y = 1.029x - 0.035 mmol/L (r = 0.976; [S.sub.y|x] = 0.051 mmol/L). We also determined the correlation independently for 68 patient sera samples between this proposed method (J) and the CPC method [Calcium-HRII kit (x): y = 1.036x - 0.031 mmol/L; r = 0.959; [S.sub.y|x] = 0.067 mmol/L] and the enzymatic method [Diacolor Ca kit (x): y = 1.018x + 0.001 mmol/L; r = 0.957; [S.sub.y|x] = 0.068 mmol/L].

We investigated the enzymatic kinetic assay for measuring calcium in serum with the Hitachi 7170 automated analyzer by PLD, which requires calcium for activation. The amount of choline produced is proportional to that of the calcium and is determined with COD and POD in the presence of 4-AA and EMSE as the increase in absorbance at 546 nm for the quinone dye.

Among the several substances, hemoglobin, [K[H.sub.2][PO.sub.4], sodium citrate, and EDTA influenced the results. Calcium values decreased with hemoglobin concentrations >0.5 g/L; therefore, hemolyzed serum is not a suitable specimen. On the other hand, calcium values increased with [KH.sub.2][PO.sub.4] concentration >3.0 mmol/L; therefore, in the case of high concentration of phosphorus in serum, this assay system indicates a slightly higher serum calcium value. Furthermore, calcium values decreased with sodium citrate or EDTA used for anticoagulant. Heparin-treated plasma was suitable for this calcium assay because heparin caused no significant interference. Only 1 of the 11 sera from patients with multiple myeloma showed a decreased value (-7.6%). Calcium-binding immunoglobulins, sometimes found in patients with multiple myeloma, may interfere this proposed calcium assay.

Calcium exists in normal serum in three forms: free calcium ions (calcium, ~45-50%), albumin-bound calcium (~45-50%), and calcium complexed to anions (~5-10%). Tabata et al. (8) demonstrated a [Ca.sup.2+] assay system based on the same principle that we investigated for the calcium assay in this report. They used phosphatidylcholine as substrate for PLD. DAPC is suitable for a kinetic assay because its [K.sub.m] value, 2.80 mmol/L, is large at pH 7.5 compared with the [K.sub.m] value of 0.053 mmol/L for phosphatidylcholine. calcium ions are easily combined or separated with albumin and anions; therefore, the ionic strength is easily altered. This alteration may make the [Ca.sup.2+] assay system described by Tabata et al. (8) unsuitable for routine use. In our assay system for calcium, a large excess of bovine albumin was added to the reaction system to maintain the calcium values. This added bovine albumin successfully prevent calcium values variation related to the albumin concentration in the serum.

This method had good precision, good analytical recovery, andgood correlation with AAS and the conventional methods. This new enzymatic method can be rapidly and easily performed, which makes it suitable as a routine procedure for serum calcium determination.

We thank K. Kubono of SRL, Inc. (Tokyo, Japan) for measuring the calcium in the patient sera by AAS.


(1.) Paul Cali J, Bowers GN Jr, Young DS, Gambino SR, Gochman N, Mather A, et al. A referee method for the determination of total calcium in serum. Clin Chem 1973;19:1208-13.

(2.) Kessler G, Wolfman M. An automated procedure for the simultaneous determination of calcium and phosphorus. Clin Chem 1964;10:686-703.

(3.) Harold V, Connerty MD, Anglis R, Briggs BS. Determination of serum calcium by means of orthocresolphthalein complexone. Am J Clin Pathol 1966;45: 290-6.

(4.) Gitelman HJ. An improved automated procedure for the determination of calcium in biological specimens. Anal Biochem 1967;18:521-31.

(5.) Sunderland MLE, Weatherburn MW, Logan JE. Observation on diagnostic kits for the determination of calcium in serum. Clin Biochem 1971;4:16-21.

(6.) Barnett RN, Skodon SB, Goldberg MH. Performance of "kits" used for clinical chemical analysis of calcium in serum. Am J Clin Pathol 1973;59:836-45.

(7.) Kayamori Y, Katayama Y. Enzymatic method for assaying calcium in serum and urine with porcine pancreatic a-amylase. Clin Chem 1994;40:781-4.

(8.) Tabata M, Kido T, Ikemoto M, Totani M, Murachi T. Use of phospholipase D and choline oxidase for the enrymatic determination of calcium ion in serum. J Clin Biochem Nutr 1986;1:11-9.

(9.) Kimura S, lyama S, Yamaguchi Y, Hayashi S, Fushimi R, Amino N. New enrymatic assay for calcium in serum. Clin Chem 1996;42:1202-5.

D, Yoshitaka Morishita, [1] Yoshitsugu Iinuma, [1] * Nobuo Nakashima, [1] Akira Kadota, [2] Akira Miike, [2] and Toshio Tadano [2] ([1] Department of Clinical Laboratory, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan; [2] Research Laboratories, Kyowa Medex Co., Ltd., 600-1 Minamusshiki, Nagaizumi-cho, Sunto-gun, Shizuoka 411-0932, Japan; * author for correspondence: fax 81-52-744-2613, e-mail
Table 1. Precision of the proposed calcium assay.

 Pooled Pooled Pooled
 serum L serum M serum H

Within-assay (n = 20)

Mean, mmol/L 1.916 2.254 2.654
SD, mmol/L 0.0086 0.0116 0.0146
CV, % 0.45 0.51 0.55

Day-to-day (n = 10)

Mean, mmol/L 1.93 2.283 2.705
SD, mmol/L 0.0231 0.0271 0.0501
CV, % 1.2 1.2 1.8
COPYRIGHT 1999 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Technical Briefs
Author:Morishita, Yoshitaka; Iinuma, Yoshitsugu; Nakashima, Nobuo; Kadota, Akira; Muke, Akira; Tadano, Tosh
Publication:Clinical Chemistry
Date:Dec 1, 1999
Previous Article:Analytical performance of microparticle enzyme immunoassay and HPLC-tandem mass spectrometry in the determination of sirolimus in whole blood.
Next Article:Reference interval computation using robust vs parametric and nonparametric analyses.

Related Articles
Does bilirubin cause interference in Roche creatinine methods?
Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine...
Assay for free and total carnitine in human plasma using tandem mass spectrometry.
Endpoint colorimetric method for assaying total cholesterol in serum with cholesterol dehydrogenase.
An IgM paraprotein causing a falsely low result in an enzymatic assay for acetaminophen.
New enzymatic assay using phospholipase D to measure total calcium in serum.
Kinetic assay of serum and urine for urea with use of urease and leucine dehydrogenase.
Development of a novel enzymatic cycling assay for total homocysteine.
Automated enzymatic assay for measurement of lithium ions in human serum.
Development of an automated enzymatic assay for the determination of glycated serum protein in human serum.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters